Savara Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 0.66
Market capitalization 187.03M
Operating cash flow -35.27M
ESG Scores unknown

Company description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio11.26
Working Capital-0.29
Return On Equity-0.3
Debt To Equity0.12
Fixed Asset Ratio0.07
Fixed Interest Cover-17.81

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 1.55M 568k -1.14M -1.76M
Total Cashflows From Investing Activities -13.62M 15.74M 9.05M -69.46M
Net Borrowings 8.82M -41k -514k
Total Cash From Financing Activities 55.19M 54.91M 3.69M 120.81M
Change To Operating Activities 900k 279k -565k -1.08M
Issuance Of Stock 46.37M 54.95M 4.2M 85.91M
Net Income -61.52M -78.17M -49.62M -43.01M
Change In Cash 2.18M 25.5M -26.92M 11.13M
Effect Of Exchange Rate -119k -22k 170k -137k
Total Cash From Operating Activities -39.27M -45.12M -39.84M -40.08M
Depreciation 526k 1.01M 693k 367k
Change To Account Receivables
Other Cashflows From Financing Activities 34.98M 34.98M 34.98M 34.98M
Change To Netincome 18.8M 30.61M 10.28M 4.86M
Capital Expenditures -141k -148k -47k -57k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 37.17M
Income Before Tax -68.57M -78.17M -49.62M -43.01M
Net Income -61.52M -78.17M -49.62M -43.01M
Selling General Administrative 10.39M 12.86M 11.96M 12.35M
Gross Profit -38.78M -34.78M -28.99M
Ebit -46.63M -50.74M -46.11M -40.63M
Operating Income -46.63M -50.74M -46.11M -40.63M
Interest Expense -70k -70k -1.48M -2.28M
Income Tax Expense -7.06M
Total Revenue 257k
Cost Of Revenue 38.78M 35.04M 28.99M
Total Other Income ExpenseNet -21.94M -27.43M -3.51M -2.38M
Net Income From Continuing Ops -61.52M -78.17M -49.62M -43.01M
Net Income Applicable To Common Shares -61.52M -78.17M -49.62M -43.01M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 44.07M 34.51M 33.36M 32.1M
Total Stockholder Equity 108.22M 101.7M 64.38M 144.5M
Other Current Liabilities 276k
Total Assets 152.29M 136.2M 97.75M 176.6M
Common Stock 36k 52k 55k 116k
Other Current Assets 191k 591k 1.9M
Retained Earnings -129.72M -207.89M -257.51M -300.52M
Treasury Stock 200k -17k 942k 5k
Cash 24.3M 49.8M 22.88M 34.01M
Total Current Liabilities 7.25M 10.88M 8.17M 14.66M
Other Stockholder Equity 200k -17k 942k 5k
Property, Plant, and Equipment 522k 352k 156k 324k
Total Current Assets 113.34M 124.07M 85.12M 165M
Net Tangible Assets 81.3M 90.59M 52.16M 133.22M
Net Receivables 1.68M 1.62M 1.7M 1.14M
Accounts Payable 3.88M 3.41M 2.6M 1.44M


Insider Transactions

Here are the insider transactions of stock shares related to Savara Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
PRATT RAYMOND DENNIS M.D.Stock Award(Grant) at price 0.00 per share.D2022-11-21Officer150k
LOWRANCE DAVID L. CPAPurchase at price 1.14 per share.D2021-12-17Chief Financial Officer4k
LOWRANCE DAVID L. CPAStock Award(Grant) at price 0.00 per share.D2021-12-14Chief Financial Officer125k
PAULS MATTHEWStock Award(Grant) at price 0.00 per share.D2021-12-14Chief Executive Officer400k
CHOWDHURY BADRUL A. M.D. PH.D.Stock Award(Grant) at price 0.00 per share.D2021-12-14Officer125k
HAWKINS RICHARD JAMESConversion of Exercise of derivative security at price 0.55 per share.D2021-12-13Director728
CHOWDHURY BADRUL A. M.D. PH.D.Purchase at price 1.05 per share.D2021-12-09Officer25k
PAULS MATTHEWPurchase at price 1.06 per share.D2021-12-08Chief Executive Officer6.5k
ELAM NEVAN CConversion of Exercise of derivative security at price 0.55 per share.D2021-12-06Director1.17k
PAULS MATTHEWPurchase at price 1.10 per share.D2021-12-02Chief Executive Officer10k
PAULS MATTHEWPurchase at price 1.06 - 1.11 per share.D2021-11-19Chief Executive Officer22.15k
ELAM NEVAN CConversion of Exercise of derivative security at price 0.52 per share.D2021-08-18Director2.29k
PAULS MATTHEWPurchase at price 1.18 - 1.19 per share.D2021-08-18Chief Executive Officer26.9k
PAULS MATTHEWPurchase at price 1.63 per share.D2021-05-21Chief Executive Officer10k
CHOWDHURY BADRUL A. M.D. PH.D.Sale at price 1.56 per share.D2021-05-17Officer50k
CHOWDHURY BADRUL A. M.D. PH.D.D2021-05-14Officer200k
PAULS MATTHEWPurchase at price 1.82 per share.D2021-04-19Chief Executive Officer27.4k
PAULS MATTHEWPurchase at price 2.07 per share.D2021-03-22Chief Executive Officer24.1k
LOWRANCE DAVID L. CPAPurchase at price 1.45 per share.D2021-03-15Chief Financial Officer13.79k
MCCRACKEN JOSEPH SPurchase at price 1.45 per share.D2021-03-15Director68.97k
PAULS MATTHEWPurchase at price 1.74 per share.D2021-02-22Chief Executive Officer28.7k
ELAM NEVAN CConversion of Exercise of derivative security at price 0.52 per share.D2020-12-15Director2.93k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Savara Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Savara Inc

Here is the result of two systematic investment strategies applied to Savara Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Savara Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Savara Inc:

Savara Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -45.75% on the backtest period.

Performance at glance

Performance

-45.75 %

Latent gain

-1028.28 $

Invested capital

2247.68 $

Annualized return

-11.05 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Savara Inc

This is the result of two momentum investment strategies applied to Savara Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Savara Inc

The following chart shows all the entries opened by the momentum investment system on Savara Inc:

Savara Inc momentum entries
  • The first momentum investment strategy would give -39.58% of return on Savara Inc. That represents -1781.57$ of latent gain with 4501.17$ of employed capital.
  • The second momentum investment strategy would give -30.12% of return on Savara Inc. That represents -755.3$ of latent gain with 2507.7$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-39.58 %

Latent gain

-1781.57 $

Invested capital

4501.17 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-30.12 %

Latent gain

-755.3 $

Invested capital

2507.7 $

Annualized return

-8.23 %

Momentum equity curve on Savara Inc

The following chart shows the equity curve of the two momentum strategies applied to Savara Inc:

Savara Inc momentum equity

Note: the dividends potentially given by Savara Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Savara Inc

The following chart shows the employed capital evolution of the two momentum strategies on Savara Inc since the beginning:

Savara Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Savara Inc

Buy the dip entry openings on Savara Inc

Savara Inc

The performance achieved by the robo-advisor on Savara Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Savara Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Savara Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Savara Inc

The following chart shows the result of the investment strategy applied to Savara Inc:

Savara Inc

Note: the dividends potentially given by Savara Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Savara Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Savara Inc:

Savara Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Savara Inc

In this section, I will compare the three previous investment strategies applied to Savara Inc.

Equity curve comparison on Savara Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Savara Inc investment strategy comparison

Employed capital comparison on Savara Inc

Savara Inc investment comparison

Performance comparison on Savara Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -45.75% -1028.28$ 2247.68$ -11.05%
Momentum 1 quarter -39.58% -1781.57$ 4501.17$ -10.15%
Momentum 2 quarters -30.12% -755.3$ 2507.7$ -8.23%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-11.05 %

Momentum 1Q

-8.23 %

Momentum 2Q

-8.23 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Savara Inc:

Positive correlations

Most correlated stocks this year

  • Savara Inc

  • Most correlated stocks last 3 months

  • Savara Inc
  • NOVACON TECH

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • MAUREL ET PROM
  • IMERYS

  • Note: The algorithm computes the probability of correlation between Savara Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Savara Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Savara Inc
    Country United States
    City Austin
    Address Building III
    Phone 512 614 1848
    Website www.savarapharma.com
    FullTime employees 22
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker SVRA
    Market www.nasdaq.com

    Savara Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown